Yuan Xue

Yuan Xue Ph.D. brings to Accutar Biotech over 12 years of experience in clinical drug development and translational research from pharma and academia. Most recently, he was a Senior Director of Global Regulatory Affair Oncology & In-vitro Diagnostics at Merck. In this role, he oversaw the global regulatory strategy throughout Phase 1 – 3 under the Keytruda® renal cell carcinoma program. He led the cross-functional teams to achieve the global registrations and approval of Welireg® (belzutifan). Previously at Bayer, Yuan was responsible for developing the global regulatory strategies for early- and late-stage oncology programs, including Vitrakvi® (larotrectinib), Xofigo® (radium-223) and Nexavar® (sorafenib). Yuan obtained his Ph.D. in Medicine from the Karolinska Institute, and completed postdoctoral fellowship at the Langer Lab at the Massachusetts Institute of Technology. He is the leading author of more than 15 publications in scientific journals including Nature Medicine, Cell Metabolism and PNAS.